Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide study
Abstract This retrospective cohort study included all user of tumor necrosis factor-α inhibitors (TNFi), including etanercept, infliximab, adalimumab, and golimumab, among Korean patients with psoriasis and rheumatoid arthritis (N of user = 7,645) and the non-user who was diagnosed with same disease...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-03-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-90996-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850029755787640832 |
|---|---|
| author | Jihun Song Seong Rae Kim Yu-Jin Kim Sun Jae Park Seogsong Jeong Sang Min Park |
| author_facet | Jihun Song Seong Rae Kim Yu-Jin Kim Sun Jae Park Seogsong Jeong Sang Min Park |
| author_sort | Jihun Song |
| collection | DOAJ |
| description | Abstract This retrospective cohort study included all user of tumor necrosis factor-α inhibitors (TNFi), including etanercept, infliximab, adalimumab, and golimumab, among Korean patients with psoriasis and rheumatoid arthritis (N of user = 7,645) and the non-user who was diagnosed with same diseases, never used TNFi, and was served as the reference. Cumulative usage of TNFi was calculated between the newly diagnosed date and index date (2-year from the diagnosed date). Adjusted hazard ratio (aHR [95% confidence intervals (CIs)]) for colorectal, liver, lung, kidney, breast, and thyroid cancer were not significantly increased or decreased: 0.92 [0.61–1.38], 0.90 [0.53–1.53], 1.00 [0.73–1.37], 1.20 [0.62–2.34], 0.91 [0.62–1.34], and 0.91 [0.66–1.26], respectively. The increased risk of lymphoma in the infliximab user (2.49 [1.33–4.66]; p < 0.01) was statistically significant. Similarly, the risk of leukemia increased significantly in the etanercept (3.87 [1.71–8.76]; p < 0.01) and adalimumab (3.36 [1.65, 6.84]; p < 0.001) user. Accumulated prescriptions of TNFi for two years did not increase the incidence of cancer, except lymphoma and leukemia. Since the use of TNFi increases the risk of leukemia and lymphoma, a decision for frequent prescription of TNF-α inhibitors should be more careful. |
| format | Article |
| id | doaj-art-6a14496dfd6c4bd1835fefaa3e3dfa58 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-6a14496dfd6c4bd1835fefaa3e3dfa582025-08-20T02:59:24ZengNature PortfolioScientific Reports2045-23222025-03-011511810.1038/s41598-025-90996-zRisk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide studyJihun Song0Seong Rae Kim1Yu-Jin Kim2Sun Jae Park3Seogsong Jeong4Sang Min Park5Department of Biomedical Sciences, Seoul National University Graduate SchoolDepartment of Dermatology, Seoul National University College of MedicineCenter for Biomaterials, Biomedical Research Institute, Korea Institute of Science and TechnologyDepartment of Biomedical Sciences, Seoul National University Graduate SchoolDepartment of Biomedical Informatics, Korea University College of MedicineDepartment of Biomedical Sciences, Seoul National University Graduate SchoolAbstract This retrospective cohort study included all user of tumor necrosis factor-α inhibitors (TNFi), including etanercept, infliximab, adalimumab, and golimumab, among Korean patients with psoriasis and rheumatoid arthritis (N of user = 7,645) and the non-user who was diagnosed with same diseases, never used TNFi, and was served as the reference. Cumulative usage of TNFi was calculated between the newly diagnosed date and index date (2-year from the diagnosed date). Adjusted hazard ratio (aHR [95% confidence intervals (CIs)]) for colorectal, liver, lung, kidney, breast, and thyroid cancer were not significantly increased or decreased: 0.92 [0.61–1.38], 0.90 [0.53–1.53], 1.00 [0.73–1.37], 1.20 [0.62–2.34], 0.91 [0.62–1.34], and 0.91 [0.66–1.26], respectively. The increased risk of lymphoma in the infliximab user (2.49 [1.33–4.66]; p < 0.01) was statistically significant. Similarly, the risk of leukemia increased significantly in the etanercept (3.87 [1.71–8.76]; p < 0.01) and adalimumab (3.36 [1.65, 6.84]; p < 0.001) user. Accumulated prescriptions of TNFi for two years did not increase the incidence of cancer, except lymphoma and leukemia. Since the use of TNFi increases the risk of leukemia and lymphoma, a decision for frequent prescription of TNF-α inhibitors should be more careful.https://doi.org/10.1038/s41598-025-90996-zCohort studyTNF-alphaCancerLeukemiaLymphoma |
| spellingShingle | Jihun Song Seong Rae Kim Yu-Jin Kim Sun Jae Park Seogsong Jeong Sang Min Park Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide study Scientific Reports Cohort study TNF-alpha Cancer Leukemia Lymphoma |
| title | Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide study |
| title_full | Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide study |
| title_fullStr | Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide study |
| title_full_unstemmed | Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide study |
| title_short | Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide study |
| title_sort | risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term tnf α inhibitors a retrospective nationwide study |
| topic | Cohort study TNF-alpha Cancer Leukemia Lymphoma |
| url | https://doi.org/10.1038/s41598-025-90996-z |
| work_keys_str_mv | AT jihunsong riskofhematologicmalignanciesinpsoriasisandrheumatoidarthritispatientsusinglongtermtnfainhibitorsaretrospectivenationwidestudy AT seongraekim riskofhematologicmalignanciesinpsoriasisandrheumatoidarthritispatientsusinglongtermtnfainhibitorsaretrospectivenationwidestudy AT yujinkim riskofhematologicmalignanciesinpsoriasisandrheumatoidarthritispatientsusinglongtermtnfainhibitorsaretrospectivenationwidestudy AT sunjaepark riskofhematologicmalignanciesinpsoriasisandrheumatoidarthritispatientsusinglongtermtnfainhibitorsaretrospectivenationwidestudy AT seogsongjeong riskofhematologicmalignanciesinpsoriasisandrheumatoidarthritispatientsusinglongtermtnfainhibitorsaretrospectivenationwidestudy AT sangminpark riskofhematologicmalignanciesinpsoriasisandrheumatoidarthritispatientsusinglongtermtnfainhibitorsaretrospectivenationwidestudy |